Announced details
Relapsed or refractory acute myeloid leukemia (AML)
The administrative authority and subcommittee reviewing rogocekib for orphan drug designation. Capital and personnel relationships are Not disclosed.
The Pharmaceutical Affairs and Food Sanitation Council's Second Subcommittee on Pharmaceuticals is a subcommittee of the Pharmaceutical Affairs and Food Sanitation Council, which is established within the Ministry of Health, Labour and Welfare. Other information on its location, representative, capital and year of establishment is Not disclosed.
Orphan drug designation (review toward designation in Japan)
Ministry of Health, Labour and Welfare
The transaction will have no impact on the Company's financial results.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib (development code: CTX-712) |
| Counterparty | The Pharmaceutical Affairs and Food Sanitation Council's Second Subcommittee on Pharmaceuticals, Ministry of Health, Labour and Welfare |
| Counterparty overview | The Pharmaceutical Affairs and Food Sanitation Council's Second Subcommittee on Pharmaceuticals is a subcommittee of the Pharmaceutical Affairs and Food Sanitation Council, which is established within the Ministry of Health, Labour and Welfare. Other information on its location, representative, capital and year of establishment is Not disclosed. |
| Relationship with the Company | The administrative authority and subcommittee reviewing rogocekib for orphan drug designation. Capital and personnel relationships are Not disclosed. |
| Applicable area | Relapsed or refractory acute myeloid leukemia (AML) |
| Award/certification name | Orphan drug designation (review toward designation in Japan) |
| Awarding / certifying body | Ministry of Health, Labour and Welfare |
| Impact on Business Performance | The transaction will have no impact on the Company's financial results. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The designation was approved by the Pharmaceutical Affairs and Food Sanitation Council's Second Subcommittee on Pharmaceuticals during its review toward orphan drug designation for relapsed or refractory acute myeloid leukemia (AML).